TY - CHAP AU - Shin'Ichi Takeda AU - Takashi Okada ED - Ke Xu Y1 - 2011-07-20 PY - 2011 T1 - Progress and Challenges in AAV-Mediated Gene Therapy for Duchenne Muscular Dystrophy N2 - The development of technologies that allow targeting of specific cells has progressed substantially in recent years for several types of vectors, particularly viral vectors, which have been used in 70% of gene therapy clinical trials. Particular viruses have been selected as gene delivery vehicles because of their capacities to carry foreign genes and their ability to efficiently deliver these genes associated with efficient gene expression. This book is designed to present the most recent advances in viral gene therapy BT - Viral Gene Therapy SP - Ch. 11 UR - https://doi.org/10.5772/18624 DO - 10.5772/18624 SN - PB - IntechOpen CY - Rijeka Y2 - 2024-03-29 ER -